Clinical Trials at USC

1581 Results for

Study Title	Principal Investigator
Early Onset and Familial Gastric Cancer Registry Not recruiting \| Stomach Cancer \| Multisite View full trial information >>	David Kelsen
A Phase I/IIa Multi-dose Escalation Study of BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Subjects With Relapsed or Relapsed/Refractory Multiple Myeloma BT062 is an antibody-drug conjugate designed to bind and destroy Myeloma cells. The study drug is being given in multiple doses with standard Multiple Myeloma treatments, lenalidomide and dexamethasone, to test how well the treatments are tolerated and work together. This study is a dose escalation study with the purpose to find out the highest dose of BT062 that a subject can tolerate in combination with lenalidomide and dexamethasone. Not recruiting \| Blood Cancer \| Multisite View full trial information >>	Kenneth Anderson
<< < 54 55 56 57 58 ... 60 >>